Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs
Author:
Funder
Laura and John Arnold Foundation
Publisher
Elsevier BV
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference18 articles.
1. Using external reference pricing in Medicare Part D to reduce drug price differentials with other countries;Kang;Health Aff,2019
2. Sharp increase in spending and number of Part D beneficiaries using ultra-expensive drugs;Kang;Health Aff,2020
3. Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019;Dusetzina;JAMA,2019
4. Value in pharmaceutical pricing;Paris;OECD Heal Work Pap,2013
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. How Do the Institute for Clinical and Economic Review’s Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee’s Assessments of Added Benefit? A Qualitative Study;Value in Health;2024-08
2. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations;Value in Health;2023-11
3. Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs;Value in Health;2023-09
4. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance;JAMA Health Forum;2023-05-26
5. Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare;JAMA;2023-04-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3